Dosing of 2nd Cohort in Phase 1 DMT Clinical Study There are so many illnesses that still have no effective treatments despite the significant advancements in healthcare over the past century. But, with these developments and new drugs that have been created, there’s also unseen potential for drug repurposing to truly maximize the effectiveness of past discoveries. And that’s what $AGN.C is looking to do, take old, safe, and proven drugs to repurpose them for novel uses to fully maximize their potential healing effects.
They recently announced the successful dosing of the second cohort of patients in their Phase 1 clinical DMT study.
- The purpose of the study is to identify the safety, tolerability, and pharmacokinetics of DMT when administered as an intravenous bolus followed by a prolonged infusion of 6 hours, a period which has never been studied clinically.
- They’re doing this as DMT has the potential to become a promising treatment to help stroke victims recover due to its properties to have neuroplastic and neurogenesis effects on the brain, which help stroke victims recover the damaged brain connections.
- With nearly 800,000 people each year experiencing a stroke in the US alone, this provides a huge market opportunity and can be a life-changing form of treatment for many.
https://ca.finance.yahoo.com/news/algernon-neuroscience-announces-successful-dosing-110000192.html
With DMT being just one among a number of promising drug repurposing research that $AGN.C is conducting, there’s a lot of upside potential, especially considering the current $2.5M market cap. Definitely keep an eye out as they continue to progress with their research.